PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.
about
KRAS mutational analysis for colorectal cancer. Application: pharmacogenomicMulti-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancerDeregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimusPredictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of OptionsMolecular testing to optimize therapeutic decision making in advanced colorectal cancerKirsten Ras* oncogene: Significance of its discovery in human cancer researchAdvances in targeted and immunobased therapies for colorectal cancer in the genomic eraPharmacologic resistance in colorectal cancer: a reviewClinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancerTreatment Individualization in Colorectal CancerPersonalized treatment for advanced colorectal cancer: KRAS and beyondEGFR/HER-targeted therapeutics in ovarian cancerTargeting tyrosine kinases in cancer: the converging roles of cytopathology and molecular pathology in the era of genomic medicinePTEN modulators: a patent reviewPTEN plasticity: how the taming of a lethal gene can go too farColorectal Cancer Biomarkers: Where Are We Now?Turning off AKT: PHLPP as a drug targetPrimary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesAcquired resistance to EGFR-targeted therapies in colorectal cancerKRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.Therapeutic targeting of cancers with loss of PTEN function.The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.A perspective on anti-EGFR therapies targeting triple-negative breast cancerTherapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidenceMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerThe Role of PTEN in Tumor AngiogenesisRegulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling1, 9-Pyrazoloanthrones downregulate HIF-1α and sensitize cancer cells to cetuximab-mediated anti-EGFR therapyDifluorinated-curcumin (CDF) restores PTEN expression in colon cancer cells by down-regulating miR-21Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell CarcinomaRAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data.The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study.Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival.Systems approach for the selection of micro-RNAs as therapeutic biomarkers of anti-EGFR monoclonal antibody treatment in colorectal cancer.The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancerPrognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients.
P2860
Q21128654-07C19E91-EAB4-47E6-8CAC-3215AC294E36Q21142734-EAF331C2-CC06-45CF-AAD7-1D4F471AE1B2Q24600932-DF6D6220-6008-46DF-A77E-2E6DF163A968Q26738655-6425F754-123A-4DE6-80A4-4358BAB4E9B8Q26749012-CBABCA55-9728-436B-AB7B-A03E50AE59D5Q26751212-ED03F2E6-A811-48F5-A7C3-014BCDE091B6Q26751344-F9BCE7D2-1050-43ED-931C-76FB96A7511FQ26769850-25AACCBA-C6AB-42E4-B570-BE9F26145AE0Q26769958-D9A084FB-2CBA-457B-A17B-037320E530A9Q26776215-C7E2C83D-E7B1-44F9-AE3F-3839DB97881AQ26822817-A7E196C3-5EB3-4658-98B5-F8BBB594F802Q26863231-7FA57372-1713-4072-82BA-5AFAEF089421Q26865436-6E5EDC2B-8E92-4AFA-A56D-F9309470C892Q26995513-71A59B0C-ED9B-4B93-8FF3-7BCBFE831F17Q26995683-8903FA89-E6B3-4CED-A1BC-23CD9DFFD211Q27003134-577CD35F-C7D1-459B-8251-A557F5823743Q27014094-B836C7D3-A898-443A-A55B-94DD8FF47699Q27015224-B9994106-7C31-484A-B783-E60145B4D1FCQ27022741-753B7193-87D0-4B04-898C-781B51820123Q27851532-381AD9BE-9DCB-4283-92F7-5749C9CE69E9Q27851592-84D546F8-33F2-4CE2-9001-25AAF76A9BA3Q27851892-7C456E68-70C1-4D5E-A794-3245AE2F10FAQ27852057-0C919996-6956-47D5-8ADA-5CC6BB476A2BQ27852764-33BA7B17-C45E-4DB5-B49A-F15CE8BFB8E2Q27852988-6ECDFE87-DE40-44B3-9FFC-F73E18523F1BQ28069867-967688C7-4531-4D14-B850-C1E8B8A44ACEQ28071772-F84453EF-211C-499E-BEF6-2E0F0F8F5960Q28076490-2E78775E-FCEB-4A17-9546-0996E3D65EECQ28391620-7A0D0118-9267-47B3-BF61-CAE53166D6EBQ28475546-18FEE64D-2CBE-4885-A9A4-09B432B33E33Q28476652-A06F0E8F-B440-469D-AE81-CD92F31DF5D2Q28534834-F51B43B7-CCF1-403A-9565-478486D846E3Q28551507-F5127E21-726A-4D4A-B864-AD041EF67743Q30967175-CF18DE78-4A11-4BFA-9C24-5CBCFA10ECBCQ33274011-89E7BE92-19FC-4703-9A4F-1A39736DF0D5Q33359798-00F486F7-023E-4EBA-9BE7-5E2B2497EB2BQ33387448-D7E6BA3D-7AE2-466C-8F87-3D01BE3B293DQ33556004-431BCF80-2DC2-410F-9E83-74CC61A1D8DAQ33565294-9FC887E6-9BAA-434B-95E1-590D2437DD90Q33620070-82E762B3-6BF1-4FEC-AB66-19654CA83A88
P2860
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
PTEN loss of expression predic ...... ic colorectal cancer patients.
@ast
PTEN loss of expression predic ...... ic colorectal cancer patients.
@en
type
label
PTEN loss of expression predic ...... ic colorectal cancer patients.
@ast
PTEN loss of expression predic ...... ic colorectal cancer patients.
@en
prefLabel
PTEN loss of expression predic ...... ic colorectal cancer patients.
@ast
PTEN loss of expression predic ...... ic colorectal cancer patients.
@en
P2093
P2860
P356
P1476
PTEN loss of expression predic ...... ic colorectal cancer patients.
@en
P2093
A Camponovo
E Romagnani
F Molinari
L L Etienne
L Mazzucchelli
M Frattini
M Ghisletta
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604009
P407
P577
2007-10-16T00:00:00Z